Ocugen Sets Ambitious Three-BLA Goal by 2027 After $130M Convertible Bolsters Balance Sheet

Ocugen plans three BLA submissions by 2027 after $130M convertible note raise, with Q1 net loss of $19.2M and stock down 46% from highs.

Ocugen has laid out one of the most aggressive regulatory calendars in its history, targeting three Biologics License Applications over the next three years. The gene therapy developer’s push toward multiple FDA filings comes on the heels of a $130 million convertible note placement that extends its cash runway into 2028—a crucial cushion as it races to deliver clinical milestones.

The company upsized its originally planned $115 million private placement after the initial purchaser fully exercised a $15 million overallotment option. The senior convertible notes carry a 6.75% coupon and mature in 2034, with net proceeds of roughly $112.6 million flowing in after discounts and fees. A chunk of that money went straight toward simplifying the capital structure: Ocugen repaid around $32.7 million in outstanding principal and interest to Avenue Capital Group, trimming its debt load and interest expense.

Three Filings, Tight Timelines

The centerpiece of Ocugen’s pipeline remains OCU400, its lead gene therapy candidate for retinitis pigmentosa. A rolling BLA submission is slated to begin in the third quarter of 2026, following the completion of enrollment in the Phase 3 liMeliGhT trial. Topline data from that study are expected in the first quarter of 2027, with the filing wrapping up by the second quarter of that year.

But OCU400 is no longer the only near-term regulatory bet. Ocugen plans to start a Phase 3 study for OCU410—a therapy targeting geographic atrophy, the leading cause of irreversible vision loss in older adults—in the third quarter of 2026 as well. That program is built on Phase 2 data from the ArMaDa trial, released in March 2026, showing a 31% reduction in lesion growth versus the control group. That is roughly double the 15–22% efficacy range of currently approved treatments, and around 20% of treated patients showed no disease progression at all.

Before starting Phase 3, Ocugen expects to finalize study designs with both the FDA and the European Medicines Agency, with both discussions wrapping up in Q3 2026. A third candidate, OCU410ST for Stargardt disease, is also moving forward: topline data are due in the second quarter of 2027, and a BLA submission is targeted for mid-2027.

Financial Strain Shows in Q1

The cost of running three parallel late-stage programs is evident in the books. Ocugen posted a net loss of $19.2 million in the first quarter of 2026. Research and development spending hit $11.3 million, while general and administrative costs totaled $8.1 million—all against collaborative revenue of just $1.5 million. That top-line figure beat analyst estimates of $0.55 million, but the earnings per share of minus $0.06 came in slightly light.

The stock continues to trade under pressure. At around €1.17 per share, it has shed nearly 46% from its 52-week high set in March and lost close to a third of its value over the past 30 days. The relative strength index sits near 31, firmly in oversold territory and matching the technical reading from the previous month.

Upcoming Catalysts and Street Sentiment

Despite the bearish chart, the analyst consensus remains a “Strong Buy,” with a median price target of $10.00—still implying massive upside if the regulatory timelines hold. The next concrete catalyst could come in the third quarter, when Ocugen hopes to lock in the Phase 3 design with the FDA. If that goes as planned, it may help restore some confidence.

Ocugen is also taking its story directly to investors. It is presenting at the H.C. Wainwright Nasdaq BioConnect Conference in New York this week and will appear at the Stifel 2026 Virtual Ophthalmology Forum later in May. Those venues give management a chance to defend the packed schedule before a capital-markets audience and perhaps rebuild some of the trust that the stock’s slide has eroded.

The clock is now ticking on all three BLA submissions. The $130 million convertible has bought the company time, but the market will be watching closely to see whether those dollars translate into regulatory progress—starting with the OCU400 rolling filing this time next year.